HKI 357
| 中文名称 | HKI 357 |
|---|---|
| 中文同义词 | 化合物 T11569;化合物HKI-357;(E)-N-(4-((3-氯-4-((3-氟苄基)氧基)苯基)氨基)-3-氰基-7-乙氧基喹啉-6-基)-4-(二甲基氨基)丁-2-烯酰胺;HKI 357,ERBB2和EGFR的双重不可逆抑制剂;化合物HKI-357,10 MM DMSO 溶液 |
| 英文名称 | HKI 357 |
| 英文同义词 | HKI 357;(2E)-N-[[4-[[(3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide;2-Butenamide, N-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-, (2E)-;Inhibitor,HKI-357,ErbB-1,HER1,inhibit,NSCLCs,Epidermal growth factor receptor,HKI 357,EGFR,ERBB2,HKI357;(E)-N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide;HKI-357, 10 mM in DMSO |
| CAS号 | 848133-17-5 |
| 分子式 | C31H29ClFN5O3 |
| 分子量 | 574.05 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 848133-17-5.mol |
| 结构式 | ![]() |
HKI 357 性质
| 沸点 | 747.6±60.0 °C(Predicted) |
|---|---|
| 密度 | 1.34±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 在 DMSO 中溶解度为 100 mM,在乙醇中溶解度为 25 mM |
| 形态 | 粉末 |
| 酸度系数(pKa) | 12.37±0.43(Predicted) |
| 颜色 | 米白色至黄色 |
|
EGFR 34 nM (IC 50 ) |
ErbB2 33 nM (IC 50 ) |
HKI-357 (0.01-10 μM) is effective in suppressing ligand-induced EGFR autophosphorylation and its downstream signaling, as determined by AKT and MAPK phosphorylation in NCI-H1975 cells. HKI-357 also is effective in suppressing EGFR autophosphorylation (measured at residue Y1068), and AKT and MAPK phosphorylation in parental NCI-H1650 cells harboring the delE746-A750 EGFR mutation.
Western Blot Analysis
| Cell Line: | NCI-H1975 bronchoalveolar cell line |
| Concentration: | 0.01, 0.01, 0.1, 1 and 10 μM |
| Incubation Time: | |
| Result: | Suppressed ligand-induced EGFR autophosphorylation and its downstream signaling AKT and MAPK phosphorylation. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-103443 | HKI-357 | 848133-17-5 | 1 mg | 723元 |
| 2025/12/22 | HY-103443 | HKI 357 HKI-357 | 848133-17-5 | 5 mg | 1900元 |
